ROIV earnings date and last-quarter result: next report 2026-08-10, last quarter beat, P/E -77.58. Updated 2026-07-23.
Roivant Sciences (ROIV) Research Hub
Roivant Sciences (ROIV) trades on NASDAQ, GB in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 36.05 USD (-1.21%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -77.58, market cap 24.96B. This hub links to the full technical, earnings and options research available for ROIV.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, GB |
| Last close | 36.05 USD (-1.21%) |
| 52-week range | 29.79 USD – 42.5 USD |
| Trend regime | Range |
| 14-day RSI | 52.3 (Neutral) |
| Trailing P/E | -77.58 |
| Market cap | 24.96B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for ROIV
Covered Call on ROIV: how it works, illustrative setup around the real 36.05 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ROIV: how it works, illustrative setup around the real 36.05 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ROIV: how it works, illustrative setup around the real 36.05 USD price, max profit/loss, breakeven and when to use it. Educational.
ROIV technical analysis: range, last 36.05 USD, RSI 52.3, 52w range 29.79 USD–42.5 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ROIV in?
Roivant Sciences (ROIV) is classified under Healthcare (Biotechnology), listed on NASDAQ, GB.
Is ROIV in an uptrend or downtrend?
As of 2026-10-26, ROIV is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ROIV's trailing P/E ratio?
ROIV's trailing P/E is -77.58, with a market cap of 24.96B. See the earnings research page for full valuation detail.
When does ROIV next report earnings?
ROIV is next scheduled to report earnings on 2026-08-10.